Zacks Research Weighs in on STERIS's Q2 Earnings (NYSE:STE)

STERIS plc (NYSE:STE - Free Report) - Equities research analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of STERIS in a research report issued on Monday, July 14th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $2.47 per share for the quarter, up from their prior estimate of $2.46. The consensus estimate for STERIS's current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS's Q3 2026 earnings at $2.68 EPS, Q4 2026 earnings at $2.89 EPS, FY2026 earnings at $10.44 EPS, Q2 2027 earnings at $2.75 EPS, Q4 2027 earnings at $2.79 EPS and FY2028 earnings at $12.40 EPS.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.15. The firm had revenue of $1.48 billion during the quarter, compared to analysts' expectations of $1.47 billion. STERIS had a return on equity of 14.21% and a net margin of 11.26%. The firm's quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.58 EPS.

A number of other equities research analysts have also recently weighed in on the company. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research note on Monday, April 7th. Jefferies Financial Group initiated coverage on STERIS in a research note on Thursday, May 29th. They set a "hold" rating and a $263.00 price objective for the company. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 14th. Stephens reiterated an "overweight" rating and issued a $250.00 price target on shares of STERIS in a research note on Thursday, May 15th. Finally, JMP Securities increased their price target on STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a research note on Friday, May 16th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, STERIS presently has a consensus rating of "Moderate Buy" and a consensus price target of $266.50.

STERIS Trading Up 1.3%

Shares of NYSE STE opened at $228.79 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.96 and a quick ratio of 1.39. The stock has a market capitalization of $22.51 billion, a P/E ratio of 36.90 and a beta of 0.92. STERIS has a 1-year low of $200.98 and a 1-year high of $252.79. The business has a fifty day moving average price of $238.71 and a 200 day moving average price of $226.27.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. raised its stake in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Grove Bank & Trust raised its stake in shares of STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 142 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in STERIS during the first quarter worth about $37,000. ORG Wealth Partners LLC acquired a new stake in STERIS during the first quarter worth about $43,000. Finally, Brown Brothers Harriman & Co. grew its holdings in STERIS by 66.7% during the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 88 shares during the period. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Cary L. Majors sold 12,828 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the transaction, the senior vice president directly owned 11,372 shares in the company, valued at $2,843,909.76. This trade represents a 53.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Daniel A. Carestio sold 17,626 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $242.56, for a total value of $4,275,362.56. Following the completion of the transaction, the chief executive officer owned 51,385 shares of the company's stock, valued at approximately $12,463,945.60. The trade was a 25.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.07% of the company's stock.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 26th. Stockholders of record on Tuesday, June 10th were paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend was Tuesday, June 10th. STERIS's payout ratio is 36.77%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.